These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21971821)

  • 1. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
    Neukam K; Mira JA; Gilabert I; Claro E; Vázquez MJ; Cifuentes C; García-Rey S; Merchante N; Almeida C; Macías J; Pineda JA
    Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1225-32. PubMed ID: 21971821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.
    Bruce RD; Eiserman J; Acosta A; Gote C; Lim JK; Altice FL
    Am J Drug Alcohol Abuse; 2012 May; 38(3):206-12. PubMed ID: 22242700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS
    BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
    J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
    Kondo C; Atsukawa M; Tsubota A; Itokawa N; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Sakamoto C
    J Viral Hepat; 2012 Sep; 19(9):615-22. PubMed ID: 22863265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.
    Litwin AH; Berg KM; Li X; Hidalgo J; Arnsten JH
    BMC Infect Dis; 2011 Nov; 11():315. PubMed ID: 22078241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
    Berenguer J; von Wichmann MA; Quereda C; Miralles P; Mallolas J; López-Aldeguer J; Alvarez-Pellicer J; De Miguel J; Crespo M; Guardiola JM; Tellez MJ; Galindo MJ; Arponen S; Barquilla E; Bellón JM; González-García J;
    J Antimicrob Chemother; 2011 Dec; 66(12):2843-9. PubMed ID: 21965432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
    Rivero-Juárez A; Camacho Espejo A; Perez-Camacho I; Neukam K; Caruz A; Mira JA; Mesa P; García-Lázaro M; Torre-Cisneros J; Pineda JA; Rivero A
    J Antimicrob Chemother; 2012 Jan; 67(1):202-5. PubMed ID: 21990051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
    Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J
    Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC; Gurel E; Sayan M
    Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
    McHutchison JG; Manns M; Patel K; Poynard T; Lindsay KL; Trepo C; Dienstag J; Lee WM; Mak C; Garaud JJ; Albrecht JK;
    Gastroenterology; 2002 Oct; 123(4):1061-9. PubMed ID: 12360468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.
    Angeli E; Mainini A; Cargnel A; Uberti-Foppa C; Orani A; Carbone R; Andreoni M; Schiavini M; Giorgi R; Rizzardini G; Gubertini G;
    Curr HIV Res; 2009 Jul; 7(4):447-55. PubMed ID: 19601782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.